EY
EYE.AX
—
ASX
Advanced Medical Equipment & Technology
Eye.Ax
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
0,00 %
Op margin
-31,0 %
ROE
-47,8 %
Net margin
-31,0 %
Debt / equity
0,16
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
—
Open
—
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About
EYE.AX operates in the Advanced Medical Equipment & Technology industry, providing specialized medical equipment and technology solutions to healthcare providers and patients.
Business. EYE.AX operates in the Advanced Medical Equipment & Technology industry, providing specialized medical equipment and technology solutions to healthcare providers and patients.
Classification92 %
SectorHealthcare
Business sectorHealthcare Services & Equipment
IndustryAdvanced Medical Equipment & Technology
Generated · model-assisted
Sell-side consensus
BUY2 analysts
2 buy0 hold0 sell
Avg 12m price target0,50
Analyst recommendations
2 analysts · consensus BuyBuy2
Hold0
Sell0
12-month price target
0,50
Consensus of sell-side coverage.
At a glance
Score
—
not yet scored
Valuation
—
valuation pending
Analysts→
Buy
2 analysts · indicative
Ownership
—
not yet wired
Profitability→
-47,8 %
return on equity
Quality
—
not yet scored
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
— missing data
News & coverage
0Sector rotation
Sector1D1Mvs mkt
Materials+2,3 %+6,6 %+1,7 %
Communication Services+2,2 %−5,5 %+1,6 %
Energy+0,6 %+3,3 %+0,0 %
Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
Information Technology+0,6 %+6,7 %+0,0 %
Consumer Discretionary+0,4 %+7,6 %−0,2 %
Financials−0,3 %−2,8 %−0,9 %
Consumer Staples−0,4 %+2,5 %−1,0 %
Real Estate−0,7 %+10,9 %−1,3 %
Industrials−1,9 %−3,1 %−2,5 %
Utilities−1,9 %+28,2 %−2,5 %
Developing storylines
No tracked sagas currently linked to EYE.AX. Browse all sagas →
Analysis
AI analysis
Generated · analysis pipeline · tier hybrid · as of 2026-08-04
↑ At a glance
Opportunity
— missing data
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
— missing data
Signals & dispatch
peak dispatch · —
Composite-score breakdown
Synthesis
Business
EYE.AX operates in the Advanced Medical Equipment & Technology industry, providing specialized medical equipment and technology solutions to healthcare providers and patients.
Classification92 %
SectorHealthcare
Business sectorHealthcare Services & Equipment
IndustryAdvanced Medical Equipment & Technology
AI synthesis
GENERATEDEYE.AX has a liquidity position characterized by a current ratio of 2.39, indicating the company has sufficient current assets to cover its current liabilities more than twice over. The company holds cash and equivalents of 5,055,000 AUD, which is a significant portion of its total assets of 26,504,000 AUD. However, the company's operating cash flow is negative at -6,150,000 AUD, and its free cash flow is also negative at -7,228,000 AUD, suggesting that the company is not generating positive cash from its operations.
Profitability metrics for EYE.AX are concerning, with a return on equity of -47.76% and a return on assets of -34.18%. These figures indicate that the company is not generating returns for its shareholders or effectively utilizing its assets. The operating income is negative at -9,059,000 AUD, and the net income is also negative at the same amount, reflecting a significant loss for the company.
Geographically and segment-wise, EYE.AX's revenue concentration is not explicitly detailed in the available data. However, the company's operations are primarily focused on the Advanced Medical Equipment & Technology industry, which is a specialized segment within the broader healthcare sector. The company's exposure to this segment is significant, and its performance is closely tied to the demand for advanced medical equipment and technology solutions.
The growth trajectory of EYE.AX is currently negative, with a net loss of 9,059,000 AUD. The company's revenue for the period was 29,267,000 AUD, but this does not provide a clear indication of future growth without historical data for comparison. The negative operating and net income suggest that the company is not on a positive growth path and may need to address its operational inefficiencies to improve its financial performance.
Risk factors for EYE.AX include its negative profitability and cash flow, which could impact its ability to sustain operations and meet financial obligations. The company's liquidity risk is assessed as low, and there are no immediate filing-based liquidity or dilution flags. However, the company's negative operating cash flow and free cash flow indicate potential liquidity challenges in the future. The dilution risk is also assessed as low, with no immediate filing-based dilution flags detected.
Recent events and filings for EYE.AX do not indicate any significant changes or developments that would impact the company's financial position or operations. The company's analyst estimates suggest a mean price target of 0.50 AUD, with a mean recommendation of 2.00, indicating a neutral stance from analysts. The lack of strong buy recommendations and the presence of two buy recommendations suggest that analysts are cautious about the company's future performance.
Key takeaways
- EYE.AX has a strong current ratio of 2.39, indicating sufficient liquidity to cover current liabilities.
- The company is experiencing significant losses, with a return on equity of -47.76% and a return on assets of -34.18%.
- EYE.AX's operating and free cash flows are negative, suggesting operational inefficiencies and potential liquidity challenges.
- Analysts have a neutral stance on EYE.AX, with a mean recommendation of 2.00 and a mean price target of 0.50 AUD.
- The company's risk assessment indicates low liquidity and dilution risks, but its financial performance remains a concern.
Bull / Bear case
analysis pipeline— missing data
In focus — financials by report
Valuation
Market price
A$0,12
Market cap
—
Enterprise valueⓘ
—
P/Eⓘ
—
Non-GAAP P/Eⓘ
—
EV / Revenueⓘ
—
EV / Op incomeⓘ
—
EV / OCFⓘ
—
P / Bⓘ
—
P / Tangible bookⓘ
—
Tangible book
A$19.0M
Net cashⓘ
A$2.0M
Current ratioⓘ
2.4
Debt / equityⓘ
0.2
ROAⓘ
-34.2%
ROEⓘ
-47.8%
Cash conversionⓘ
68.0%
CapEx / revenueⓘ
-1.5%
SBC / revenueⓘ
—
Dilution ratioⓘ
0.0%
Revenue by segment
Business relationships
Business relationships9 disclosed relationships · 2 types · extracted from filings & disclosures
Partners1
Walmart IncWMT.OPartner95%Source ↗
Subsidiaries8
EX21:11d410bc6946EX21:11d410bc6946Subsidiarie97%
EX21:182ed95f518bEX21:182ed95f518bSubsidiarie97%
EX21:1b89db76ac2fEX21:1b89db76ac2fSubsidiarie97%
EX21:2b4ce5948c05EX21:2b4ce5948c05Subsidiarie97%
EX21:c29c17f60ad9EX21:c29c17f60ad9Subsidiarie97%
EX21:cf2f47586901EX21:cf2f47586901Subsidiarie97%
EX21:d27274dedce0EX21:d27274dedce0Subsidiarie97%
EX21:d3e634d7f1bbEX21:d3e634d7f1bbSubsidiarie97%
Supply chain
Vendors → EYE ↔ Partners → Customers · click any node to drill
1 mention in 10-K0 from corporate websites0 from news dispatches
Updated 2026-06-24Peer comparison
— missing data
Market position
Stress test
— missing data
Predictor forecast
Next quarternear-term
Earnings · next quarterconf 45 %
EPS
Consensus EPS
-0,01
Predicted surprise
+0,00
Beat probability
45 %
Analysts
2
Other metrics
Revenue
—
no estimate
Segment revenue
—
no estimate
Margin
—
no estimate
Segment margin
—
no estimate
as of 2026-05-07 · Earnings Surprise V1
Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
Full fiscal year~1 year ahead
Full fiscal year · our forecast vs guidance vs consensus
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -0,01 |
| Revenue | —no estimate | —no estimate | 33,8M AUD |
| Operating income | —no estimate | —no estimate | -4,8M AUD |
Full-year consensus mean (period as reported by source) · consensus in AUD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
Probabilistic model output — not investment advice. · generated 2026-08-04
Options
— missing data
Short squeeze
— missing data
Earnings-call key lines
— missing data
Consensus distribution
sell-side coverageRecommendation distribution2 analysts
Strong buy0
Buy2
Hold0
Sell0
Strong sell0
12-month price targetA$0,50 · Median A$0,50
Low A$0,50High A$0,50
Operating income · consensus-4,8M AUD
EPS surprise
−300,0 %
reported vs consensus · miss
Revenue surprise
−13,3 %
reported vs consensus · miss
Estimate revisions
consensus EPS · 26-week trend— missing data
Sell-side observations
LowA$0,50
MeanA$0,50
MedianA$0,50
HighA$0,50
SpotA$0,12
+316.7 %implied to mean12-month sell-side price targets · ▲ spot
Themes
— missing data
ESG
— missing data
Risk factors
Dilution riskLow
Liquidity riskLow
Filing-based flags
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Op Margin-30,9 %Below median
Net Margin-30,9 %Below median
ROE-47,8 %Bottom quartile
Capex / Rev-1,5 %Above median
D/E0,16Below median
Cash Conv0,68Below median
Corporate actions / M&A
— missing data
FX exposure
— missing data
Comparable transactions
— missing data
Derivatives & instruments
Derivative transactions
Net acquired 27 553 sh14 exercises · 10 grants10 insiders
- Director, Chief Executive Officer · Restricted Stock Units → Common StockDisposed 13 768exercise · 2026-07-31
- President, America's Best · Restricted Stock Units → Common StockDisposed 11 728exercise · 2026-07-08
- Chief Legal & Strategy Officer · Restricted Stock Units → Common StockDisposed 1 890exercise · 2026-04-29
- Chief Financial Officer · Restricted Stock Units → Common StockDisposed 26 082exercise · 2026-03-31
- Chief Technology Officer · Restricted Stock Units → Common StockAcquired 10 753grant · 2026-03-06
- Director, Executive Chairman · Restricted Stock Units → Common StockAcquired 71 685grant · 2026-03-06
- Director, Executive Chairman · Restricted Stock Units → Common StockDisposed 54 824exercise · 2026-03-06
- Director, Chief Executive Officer · Restricted Stock Units → Common StockAcquired 62 725grant · 2026-03-06
- Director, Chief Executive Officer · Restricted Stock Units → Common StockDisposed 27 412exercise · 2026-03-06
- Chief Financial Officer · Restricted Stock Units → Common StockAcquired 17 922grant · 2026-03-06
- Chief Legal & Strategy Officer · Restricted Stock Units → Common StockAcquired 10 753grant · 2026-03-06
- Chief Legal & Strategy Officer · Restricted Stock Units → Common StockDisposed 10 279exercise · 2026-03-06
- Chief People Officer · Restricted Stock Units → Common StockAcquired 10 753grant · 2026-03-06
- Chief People Officer · Restricted Stock Units → Common StockDisposed 8 224exercise · 2026-03-06
- President, America's Best · Restricted Stock Units → Common StockAcquired 10 753grant · 2026-03-06
- President, America's Best · Restricted Stock Units → Common StockDisposed 13 706exercise · 2026-03-06
- Chief Brand & Mktg Officer · Restricted Stock Units → Common StockAcquired 10 753grant · 2026-03-06
- Chief Brand & Mktg Officer · Restricted Stock Units → Common StockDisposed 8 224exercise · 2026-03-06
- Head of Emerging Brands · Restricted Stock Units → Common StockAcquired 10 753grant · 2026-03-06
- Head of Emerging Brands · Restricted Stock Units → Common StockDisposed 8 224exercise · 2026-03-06
- SVP, CHIEF MERCH. & MC OFFICER · Restricted Stock Units → Common StockAcquired 10 753grant · 2026-03-06
- Head of Emerging Brands · Restricted Stock Units → Common StockDisposed 2 989exercise · 2026-03-03
- Chief Brand & Mktg Officer · Restricted Stock Units → Common StockDisposed 6 350exercise · 2026-03-03
- SVP, Chief People Officer · Restricted Stock Units → Common StockDisposed 6 350exercise · 2026-03-03
Actions
Ask Handelsavisen
— missing data
Data sources
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
How metrics are computed
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
Source documents
- EYE.AX Market data — financials · 2026-05-27
- Nova Eye Medical Ltd Market data — analyst estimates · 2026-05-27
Ownership & reference
Leadership
- Victor PrevinExecutive Chairman of the Board
Insider activity
Net selling1 buys · 3 sellsnet -$498K16 insiders · last 365d
- Director, Chief Executive Officer · Common StockOther 13 768 · 2026-07-31
- Director, Chief Executive Officer · Common StockOther 6 660 @ $22,04$147K · 2026-07-31
- President, America's Best · Common StockOther 4 964 @ $19,41$96K · 2026-07-08
- President, America's Best · Common StockOther 11 728 · 2026-07-08
- Director · Common StockOther 11 350 · 2026-06-17
- Director · Common StockOther 16 258 · 2026-06-17
- Director · Common StockOther 16 258 · 2026-06-17
- Director · Common StockOther 14 571 · 2026-06-17
- Director · Common StockOther 11 350 · 2026-06-17
- Director · Common StockOther 11 350 · 2026-06-17
- Director · Common StockOther 11 350 · 2026-06-17
- Director · Common StockOther 11 350 · 2026-06-17
- Director · Common StockBought 50 000 @ $15,52$776K · 2026-06-05
- Chief Legal & Strategy Officer · Common StockOther 842 @ $22,39$19K · 2026-04-29
- Chief Legal & Strategy Officer · Common StockOther 1 890 · 2026-04-29
- Chief Financial Officer · Common StockOther 26 082 · 2026-03-31
- Chief Financial Officer · Common StockOther 9 702 @ $25,90$251K · 2026-03-31
- Director, Chief Executive Officer · Common StockSold 35 000 @ $26,54$929K · 2026-03-11
- Director, Executive Chairman · Common StockSold 7 601 @ $29,58$225K · 2026-03-06
- Head of Emerging Brands · Common StockOther 8 224 · 2026-03-06
- Head of Emerging Brands · Common StockOther 2 738 @ $27,90$76K · 2026-03-06
- Chief Brand & Mktg Officer · Common StockOther 8 224 · 2026-03-06
- Chief Brand & Mktg Officer · Common StockOther 2 430 @ $27,90$68K · 2026-03-06
- Director, Executive Chairman · Common StockSold 4 071 @ $29,57$120K · 2026-03-06
- President, America's Best · Common StockOther 13 706 · 2026-03-06
Short positioning
16.6Mshares short+0.5% vs prior
8.95days to cover
50.6%short of daily vol
1.5Kfails-to-deliver
as of 2026-07-15 · short-interest report (free)
Geographic breakdown
— missing data
Listings · one canonical issuer
all listings resolve to the canonical
EYE.AXCanonical
ASX · AUD
Intel & risk
peak dispatch · —
OSINT findings
Dilution riskLow
Liquidity riskLow
No immediate filing-based liquidity or dilution flags were detected.
Relationship graph
This companySectorPartnersSubsidiaries
Evidence & claims
From filings & derived data- Revenue (YoY) (2026-01-03 vs 2024-12-28): 9.0%Derived (calculated)
- Shareholders' equity (YoY) (2026-01-03 vs 2024-12-28): 6.5%Derived (calculated)
- Total assets (YoY) (2026-01-03 vs 2024-12-28): -1.2%Derived (calculated)
- Long-term debt (YoY) (2026-01-03 vs 2024-12-28): -29.9%Derived (calculated)
- Capex (YoY) (2026-01-03 vs 2024-12-28): -23.7%Derived (calculated)
- Net margin (FY 2026-01-03): 1.5%Derived (calculated)
- Return on equity (FY 2026-01-03): 3.4%Derived (calculated)
- Return on assets (FY 2026-01-03): 1.5%Derived (calculated)
- Current ratio (FY 2026-01-03): 0.55xDerived (calculated)
- EPS (basic) (YoY) (2026-01-03 vs 2024-12-28): 202.8%Derived (calculated)
- EPS (diluted) (YoY) (2026-01-03 vs 2024-12-28): 202.8%Derived (calculated)
- Cash & equivalents (YoY) (2026-01-03 vs 2024-12-28): -47.7%Derived (calculated)
- Operating cash flow (YoY) (2026-01-03 vs 2024-12-28): 9.5%Derived (calculated)
- Net income (YoY) (2026-01-03 vs 2024-12-28): 203.9%Derived (calculated)
- Operating income (YoY) (2026-01-03 vs 2024-12-28): 667.9%Derived (calculated)
- Operating income (annual): USD 58.83MSEC XBRL filing
- Cash & equivalents (annual): USD 38.71MSEC XBRL filing
- Shareholders' equity (annual): USD 869.53MSEC XBRL filing
- Capex (annual): USD 72.84MSEC XBRL filing
- Total assets (annual): USD 1.98BSEC XBRL filing
- Pre-tax income (annual): USD 41.68MSEC XBRL filing
- EPS (diluted) (annual): USD-PER-SHARES 0SEC XBRL filing
- EPS (basic) (annual): USD-PER-SHARES 0SEC XBRL filing
- Net income (annual): USD 29.6MSEC XBRL filing
Showing 24 of 60 surfaced claims.
Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.
The Thread
Everything we know, in order2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
2026-07-08INSIDERBanner Mark transacted 5.0k sh — President, America's Best ~$96k
2026-07-08INSIDERBanner Mark transacted 11.7k sh — President, America's Best
2026-07-08INSIDERBanner Mark disposed of 11.7k sh Restricted Stock Units — President, America's Best
2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
2026-06-17 00:00 UTCINSIDER9 insider transactions — 2026-06 · net buy $776k
2026-06-17INSIDERKelman Naomi transacted 11.3k sh — Director
2026-06-17INSIDERZulla Caitlin transacted 16.3k sh — Director
2026-06-17INSIDEROFarrell Susan C transacted 14.6k sh — Director
2026-06-17INSIDERNicholson Michael J transacted 11.3k sh — Director
2026-06-17INSIDERMcGrann James M. transacted 11.3k sh — Director
2026-06-17INSIDERJohnson Susan S transacted 11.3k sh — Director
2026-06-17INSIDERHepner Virginia A transacted 11.3k sh — Director
2026-06-17INSIDERArmario Jose transacted 16.3k sh — Director
2026-06-05INSIDERNicholson Michael J bought 50.0k sh — Director ~$776k
2026-04-29 00:00 UTCINSIDER3 insider transactions — 2026-04 1 derivative
2026-04-29INSIDERBrandman Jared transacted 1.9k sh — Chief Legal & Strategy Officer
2026-04-29INSIDERBrandman Jared transacted 842 sh — Chief Legal & Strategy Officer ~$19k
2026-04-29INSIDERBrandman Jared disposed of 1.9k sh Restricted Stock Units — Chief Legal & Strategy Officer
2026-03-31 00:00 UTCINSIDER52 insider transactions — 2026-03 · net sell $3.7M 21 derivative
2026-03-31INSIDERLaden Christopher transacted 9.7k sh — Chief Financial Officer ~$251k
2026-03-31INSIDERLaden Christopher transacted 26.1k sh — Chief Financial Officer
2026-03-31INSIDERLaden Christopher disposed of 26.1k sh Restricted Stock Units — Chief Financial Officer
2026-03-11INSIDERWilkes Alexander sold 35.0k sh — Director, Chief Executive Officer ~$929k
2026-03-06INSIDERVanDette Joseph transacted 8.2k sh — Chief Brand & Mktg Officer
2026-03-06INSIDERPatel Priti V transacted 8.2k sh — Head of Emerging Brands
2026-03-06INSIDERPatel Priti V transacted 2.7k sh — Head of Emerging Brands ~$76k
2026-03-06INSIDERVanDette Joseph transacted 2.4k sh — Chief Brand & Mktg Officer ~$68k
2026-03-06INSIDERBanner Mark transacted 13.7k sh — President, America's Best
2026-03-06INSIDERBanner Mark transacted 4.1k sh — President, America's Best ~$115k
2026-03-06INSIDERClark Bill transacted 8.2k sh — Chief People Officer
2026-03-06INSIDERClark Bill transacted 2.4k sh — Chief People Officer ~$68k
2026-03-06INSIDERBrandman Jared transacted 10.3k sh — Chief Legal & Strategy Officer
2026-03-06INSIDERVanDette Joseph disposed of 8.2k sh Restricted Stock Units — Chief Brand & Mktg Officer
2026-03-06INSIDERVanDette Joseph acquired 10.8k sh Restricted Stock Units — Chief Brand & Mktg Officer
Showing the 40 most recent of 58 entries.
The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04
Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data
Premium coverage